Novo puts $285m into monthly GLP-1 based on Ascendis tech Novo Nordisk has partnered with Ascendis Pharma on less frequently dosed drugs for obesity and other metabolic diseases, starting with a once-monthly GLP-1 receptor agonist
Understanding the Hormone Transforming Weight Loss and Metabolic Research In recent years, much attention has been paid to GLP-1 agonists like semaglutide (Wegovy) and tirzepatide (Mounjaro), which have revolutionized the treatment of obesity and type 2 diabetes
(This is why, I think, Adele hates me, Wilson wrote in an excerpt of her book published by Us Weekly
We dont have a lot of human data with prolonged exposure, other than in the context of hypoglycemia, that people have looked at, he said, so it is not clear what other effects, either beneficial or adverse, the antagonists might have
For example, an in vitro study from 2013 saw that rat cells treated with epitalon exhibited statistically significant increases in biomarkers associated with melatonin, suggesting the peptide has a direct effect on melatonin synthesis.8 Thus, epitalon helps keep your body in supply of a hormone necessary to stave off age-related diseases
Mancuso says